A new C4ADS report reveals that while only 4% of Chinese pharmaceuticals are produced in Xinjiang, FDA registrations for companies in the Uyghur region indicate that imports banned under the Uyghur Forced Labor Prevention Act (UFLPA) are still occurring. At least two Xinjiang-based pharmaceutical companies are currently FDA-registered, allowing them to import products into the United States.
- Search
- Tracking Login
- LET’S TALK